TICE BCG (BCG live)
MALIGNANT TUMOR OF URINARY BLADDER·+1
ORGANON PHARM.
Indication
Prevention of recurrent bladder carcinoma
Prevention of recurrent bladder carcinoma refers to post-resection therapeutic interventions aimed at inhibiting tumor relapse in patients previously diagnosed and treated for malignant neoplasms of the urinary bladder urothelium. Read more about Prevention of recurrent bladder carcinoma
3 drugs 2 manufacturers
Drugs that treat it
Common Prevention of recurrent bladder carcinoma therapies.
TICE BCG (BCG live)
BCG·MALIGNANT TUMOR OF URINARY BLADDER·+1
Merck Sharp & Dohme
BCG (TICE STRAIN) (BCG live)
BCG·MALIGNANT TUMOR OF URINARY BLADDER·+1
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with Prevention of recurrent bladder carcinoma preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPrevention of recurrent bladder carcinoma refers to post-resection therapeutic interventions aimed at inhibiting tumor relapse in patients previously diagnosed and treated for malignant neoplasms of the urinary bladder urothelium.
This clinical state most commonly affects older adults diagnosed with non-muscle-invasive bladder cancer following transurethral resection.
Pathophysiologically, it addresses the high biological propensity of urothelial tumors to recur through diffuse field cancerization of the urothelium, implantation of shed malignant cells, or microscopic persistence of residual neoplastic tissue.
Interventions in this setting are designed to eradicate residual occult malignant cells, prevent new mucosal tumor growth, and reduce the risk of stage or grade progression within the lower urinary tract.
- nih.gov
Prevention of recurrent bladder carcinoma refers to post-resection therapeutic interventions aimed at inhibiting tumor relapse in patients previously diagnosed and treated for malignant neoplasms of the urinary bladder urothelium This clinical state most commonly affects older adults diagnosed with non-muscle-invasive bladder cancer following transurethral resection Pathophysiologically, it addresses the high biological propensity of urothelial tumors to recur through diffuse field cancerization...
- cancer.gov
Prevention of recurrent bladder carcinoma refers to post-resection therapeutic interventions aimed at inhibiting tumor relapse in patients previously diagnosed and treated for malignant neoplasms of the urinary bladder urothelium Interventions in this setting are designed to eradicate residual occult malignant cells, prevent new mucosal tumor growth, and reduce the risk of stage or grade progression within the lower urinary tract
- nih.gov
Pathophysiologically, it addresses the high biological propensity of urothelial tumors to recur through diffuse field cancerization of the urothelium, implantation of shed malignant cells, or microscopic persistence of residual neoplastic tissue
Personalize your experience
Follow Prevention of recurrent bladder carcinoma and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.